2015 American Transplant Congress
Etanercept for Graft Versus Host Disease Following Liver Transplantation
Purpose: Graft versus host disease (GVHD) is a devastating diagnosis and treatment options, such as antithymocyte globulin (ATG), have poor response rates. With a goal…2015 American Transplant Congress
Alpha-Fetoprotein as a Modifier of Anatomic Criteria for Transplantation of HCC Patients
Background:The current listing criteria (Milan, UCSF) for Orthotropic Liver Transplants (OLT) in hepatocellular carcinoma (HCC) patients emphasize the anatomic features of the tumor such as…2015 American Transplant Congress
The Impact of Critical Illness and Pre-Transplant Hospitalization on Cost of Liver Transplantation
Surgery, Emory University School of Medicine, Atlanta, GA.
In order to understand the cost impact of hospitalization and ICU admission immediately prior to liver transplantation (LT), we obtained all hospital costs associated with…2015 American Transplant Congress
Is Transplant Volume Associated With Survival in Pediatric Liver Transplants?
Background. Center specific volume has been shown to correlate with outcomes for many procedures in the adult population. The current study was conducted to determine…2015 American Transplant Congress
Hepatocyte-Related miR-193a-3p Is Over-Expressed in Allograft Biopsy from Liver Tolerant Recipients
While liver transplantation is the treatment of choice for end-stage liver diseases, its success is compromised by the need to administer life-long immunosuppression, which negatively…2015 American Transplant Congress
Use of Tissue Plasminogen Activator (TPA) in Liver Transplantation from Donation After Cardiac Death (DCD) Donors: A Controlled Randomized Trial
Hepatobiliary and Liver Transplant Surgery, Cleveland Clinic, Cleveland, OH.
To further evaluate the impact of tPA in reduction of ITBS in livers recovered from the DCD donors we conducted a controlled randomized trial. Between…2015 American Transplant Congress
Living Donor Liver Transplantation for Biliary Atresia has Equivalent Survival and Shorter Waiting Time Compared to Deceased Donor Liver Transplantation
Purpose: To determine the benefit of living donor liver transplantation (LDLT) compared to deceased donor liver transplantation (DDLT) in the treatment of end stage liver…2015 American Transplant Congress
Efficacy of Sofosbuvir Based Therapy for Recurrent Hepatitis C After Liver Transplantation
Purpose: Evaluate outcomes of sofosbuvir-based hepatitis C therapy in liver transplant patients in a single center clinical setting, including interferon-free regimens.Methods: All patients with history…2015 American Transplant Congress
Everolimus-Based Immunosuppression Is Associated With a Reduced Risk of New-Onset Malignancies After Liver Transplantation
Background and aim: The inhibitor of the mammalian target of rapamycin (mTOR) everolimus (EVR) has shown anti-proliferative effects in experimental and clinical models. We investigated…2015 American Transplant Congress
Risk of End-Stage Renal Disease After Living Donor Liver Transplantation: Overall Incidence and Comparisons to Deceased Donor Recipients
Introduction: Since initiation of MELD-based allocation for liver transplants, the risk of end-stage renal disease (ESRD) post-liver transplantation has increased. Recent US data demonstrated comparable,…
American Transplant Congress abstracts